HDT Bio Corp. was awarded a $11 million cost-plus-fixed-fee definitive contract by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to develop and progress HDT-301, a replicon RNA encoding SARS-CoV-2 spike protein bound to lipid inorganic nanoparticle formulation, through a Phase I clinical trial. The contract was awarded under the 2020 NIAID Omnibus Broad Agency Announcement seeking proposals to develop medical countermeasures including vaccines, therapeutics, diagnostics and radiation countermeasures across five research areas. Work will be performed in Seattle, Washington over a four year period ending in June 2024 to address needs under the NIAID program. No set aside designation or major subcontractors were identified.
Generated 12/29/23, 3:45 PM